Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor.

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” said Moderna’s chief executive officer, Stéphane Bancel. “The ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Recent discussions on X about Moderna, Inc. (MRNA) have been buzzing with excitement following the company's announcement of positive late-stage trial results for its experimental mRNA-based ...